BioMarin Pharmaceutical, Inc. (BMRN)
55.95
-0.68
(-1.20%)
USD |
NASDAQ |
Oct 23, 16:00
55.96
+0.01
(+0.02%)
After-Hours: 20:00
BioMarin Pharmaceutical Enterprise Value : 14.17B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 14.17B |
| October 22, 2026 | 14.30B |
| October 21, 2026 | 14.03B |
| October 20, 2026 | 14.27B |
| October 19, 2026 | 13.92B |
| October 16, 2026 | 13.93B |
| October 15, 2026 | 14.19B |
| October 14, 2026 | 14.02B |
| October 13, 2026 | 13.87B |
| October 12, 2026 | 14.06B |
| October 09, 2026 | 13.95B |
| October 08, 2026 | 13.97B |
| October 07, 2026 | 14.03B |
| October 06, 2026 | 14.22B |
| October 05, 2026 | 14.48B |
| October 02, 2026 | 14.41B |
| October 01, 2026 | 14.65B |
| September 30, 2026 | 14.96B |
| September 29, 2026 | 14.93B |
| September 28, 2026 | 14.85B |
| September 25, 2026 | 15.01B |
| September 24, 2026 | 15.22B |
| September 23, 2026 | 15.38B |
| September 22, 2026 | 15.61B |
| September 21, 2026 | 15.74B |
| Date | Value |
|---|---|
| September 18, 2026 | 15.72B |
| September 17, 2026 | 15.94B |
| September 16, 2026 | 15.87B |
| September 15, 2026 | 15.82B |
| September 14, 2026 | 16.20B |
| September 11, 2026 | 16.06B |
| September 10, 2026 | 16.02B |
| September 09, 2026 | 15.81B |
| September 08, 2026 | 15.85B |
| September 04, 2026 | 16.22B |
| September 03, 2026 | 16.20B |
| September 02, 2026 | 16.30B |
| September 01, 2026 | 15.89B |
| August 31, 2026 | 15.97B |
| August 28, 2026 | 15.86B |
| August 27, 2026 | 15.98B |
| August 26, 2026 | 16.04B |
| August 25, 2026 | 16.14B |
| August 24, 2026 | 15.94B |
| August 21, 2026 | 16.25B |
| August 20, 2026 | 16.44B |
| August 19, 2026 | 16.76B |
| August 18, 2026 | 16.31B |
| August 17, 2026 | 16.24B |
| August 14, 2026 | 16.38B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascendis Pharma A/S | 15.57B |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Cytokinetics, Inc. | 8.598B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 44.76M |
| Revenue (Quarterly) | 996.38M |
| Total Expenses (Quarterly) | 951.62M |
| EPS Diluted (Quarterly) | 0.2302 |
| Gross Profit Margin (Quarterly) | 72.27% |
| Profit Margin (Quarterly) | 4.49% |
| Earnings Yield | 0.66% |
| Operating Earnings Yield | 5.89% |
| Normalized Earnings Yield | 3.521 |